Sysmex’s fiscal year ending March 2026 reported a decline in sales by 500 billion yen and an operating profit of 5.1 billion yen. Domestic sales declined by 13.5%, while overseas remained nearly flat. Net income decreased by 33.9%, and dividends increased to 38 yen. The company will promote a new medium-term management plan moving forward.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"6869","jir_company_name":"Sysmex Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-05-14","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/6869-20260514-01.pdf","jir_short_summary":"Sysmex's fiscal year ending March 2026 reported a decline in sales by 500 billion yen and an operating profit of 5.1 billion yen. Domestic sales declined by 13.5%, while overseas remained nearly flat. Net income decreased by 33.9%, and dividends increased to 38 yen. The company will promote a new medium-term management plan moving forward.","jir_summary":"### Performance Overview\nSysmex\u2019s fiscal year ending March 2026 reported sales of 500 billion yen, a decline of 1.7% compared to the previous year, with operating profit dropping 40.8% to 5.1 billion yen. In Japan, decreased blood testing sales impacted overall results, while overseas markets remained nearly flat, maintaining some regional growth. Net income also declined by 33.9%, and dividends increased to 38 yen. Increased R&D and selling expenses continued to suppress profits. The company has launched a new medium-term management plan to adapt to changing business environments.\n\n### Future Outlook and Strategies\nSysmex will implement a new medium-term management plan from the fiscal year ending March 2027 to March 2029, focusing on strengthening the diagnostics business and promoting healthcare DX. Although sales decline in emerging markets including China poses challenges, the launch of new products in blood coagulation and expanded overseas operations aim for sales of 535 billion yen and operating profit of 5.8 billion yen. The company is also redesigning its capital and human capital strategies to enhance corporate value.","jir_financial_highlights":"Net Sales: 500,006 million yen (YoY\u25b31.7%)\nOperating Profit: 51,831 million yen (YoY\u25b340.8%)\nNet Income Attributable to Owners of Parent: 35,457 million yen (YoY\u25b333.9%)\nDividends: 38 yen (Increase (from 17 yen previous year to 38 yen this year))\nNumber of Treasury Shares: 7,995,365 shares (From 5,873,371 shares previous year to 7,995,365 shares this year)","jir_category":"","jir_hashtags":"#Sysmex, #IRResults, #JapaneseStocks","jir_key_figures":"Net Sales: 500,006 million yen (YoY\u25b31.7%)\nOperating Profit: 51,831 million yen (YoY\u25b340.8%)\nNet Income Attributable to Owners of Parent: 35,457 million yen (YoY\u25b333.9%)","jir_meta_title":"\u3010Sysmex\u30112026 Fiscal Year Results\uff5cSales Declined but Dividends Increased to 38 Yen","jir_meta_description":"Sysmex\u2019s fiscal year ending March 2026 reported a 1.7% decrease in sales to 500 billion yen, with operating profit falling 40% to 5.1 billion yen. Dividends increased to 38 yen, and new medium-term plans are being promoted.","jir_og_title":"\u3010Sysmex\u30112026 Fiscal Year Results\uff5cSales Declined but Dividends Increased to 38 Yen","jir_og_description":"Sysmex\u2019s fiscal year ending March 2026 reports a 1.7% decrease in sales to 500 billion yen, with operating profit down 40% to 5.1 billion yen. Announcing dividend increase and new medium-term plan.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7590,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-51074","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n